Based on our findings of two phenotypes with distinct TME infiltration in patients with upregulation of PD-L1, we postulated that we should determine the response of CRC patients to immunotherapy mainly based on TME cells infiltration, especially in patients with high expression of PD-L1. The gene discussed is CD274; the disease is colorectal carcinoma.